AstraZeneca experienced positive trading momentum driven by a major regulatory catalyst in its rare disease portfolio. The U.S. Food and Drug Administration granted accelerated approval for Ultomiris (ravulizumab) to treat adults with primary immunoglobulin A nephropathy at risk of rapid disease progression. This clearance expands AstraZeneca’s commercial footprint into high-risk renal disorders, addressing a target market of over 200,000 U.S. patients. Investor enthusiasm was further supported by additional pipeline updates, including positive late-stage trial readouts for Tezspire in eosinophilic esophagitis and the U.S. availability of Zegfrovy for non-small cell lung cancer.

The expansion of key therapeutic indications reinforces…